L. Tanser

Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test.

C. Shapiro, D. Armstrong, K. Nevin, 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Do physicians correctly assess patient symptom severity in gastro‐oesophageal reflux disease?

A. Barkun, I. Wiklund, D. Armstrong, 2004, Alimentary pharmacology & therapeutics.

The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole

G. Guyatt, A. Barkun, H. Schünemann, 2005, Health and Quality of Life Outcomes.

Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

D. Armstrong, K. Nevin, S. Escobedo, 2003, Alimentary pharmacology & therapeutics.

The impact of illness in patients with moderate to severe gastro-esophageal reflux disease

G. Guyatt, P. Wahlqvist, A. Barkun, 2005, BMC gastroenterology.

A Randomized Multicenter Trial to Evaluate Simple Utility Elicitation Techniques in Patients With Gastroesophageal Reflux Disease

Gordon H Guyatt, Holger J Schünemann, David Armstrong, 2004, Medical care.

Validation of a symptom diary for patients with gastro‐oesophageal reflux disease

G. Guyatt, A. Barkun, H. Schünemann, 2006, Alimentary pharmacology & therapeutics.

The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)

G. Guyatt, P. Wahlqvist, A. Barkun, 2012, PharmacoEconomics.

The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole

L. Sharples, A. Barkun, I. Wiklund, 2005, Health and quality of life outcomes.